Sertraline in children and adolescents with major depressive disorder

Craig L. Donnelly, Karen Dineen Wagner, Moira Rynn, Paul Ambrosini, Phyllis Landau, Ruoyong Yang, Christopher J. Wohlberg

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


OBJECTIVE: To explore time to first response and time to first persistent response of sertraline versus placebo and compare these parameters between children (6-11 years old, n = 177) and adolescents (12-17 years old, n = 199) with major depressive disorder. METHOD: A 10-week placebo-controlled treatment was followed by a 24-week open-label sertraline treatment. The double-blind studies were not powered to detect efficacy differences between age groups. A post hoc analysis explored time to first response and first persistent response using the Children's Depression Rating Scale-Revised and Clinical Global Impressions-Improvement predefined criteria. RESULTS: There were no statistically significant differences in time to first response or first persistent response between sertraline and placebo in children, except for time to first response on Clinical Global Impressions-Improvement. Sertraline had a significantly faster time to first persistent response in adolescents compared to placebo. Within treatment groups, children had a significantly faster time to first response than adolescents, whether treated with placebo or sertraline, but not on time to first persistent response. Both age groups showed similar improvement over 34 weeks of treatment. CONCLUSION: In the double-blind studies, children and adolescents had different patterns of response with sertraline vs. placebo.

Original languageEnglish (US)
Pages (from-to)1162-1170
Number of pages9
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Issue number10
StatePublished - Oct 2006


  • Major depressive disorder
  • Sertraline
  • Time to response

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health


Dive into the research topics of 'Sertraline in children and adolescents with major depressive disorder'. Together they form a unique fingerprint.

Cite this